TG Therapeutics, Inc. entered into a Commercialization Agreement with Neuraxpharm Pharmaceuticals, granting them an exclusive license to commercialize BRIUMVI for multiple sclerosis in Europe and other territories, with potential milestone payments of up to $645 million.